<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01854073</url>
  </required_header>
  <id_info>
    <org_study_id>AFHSR-5-2013</org_study_id>
    <nct_id>NCT01854073</nct_id>
  </id_info>
  <brief_title>Hyoscine Butyl Bromide for Management of Prolonged Labor</brief_title>
  <official_title>Use of Hyoscine Butyl Bromide for Management of Prolonged Labor in Nulliparous Women, A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Armed Forces Hospitals, Southern Region, Saudi Arabia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the value of using Hyoscine as an antispasmodic drug for the management of&#xD;
      prolonged labor in nulliparous women at term.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Management of prolonged labor represents a challenging area in the daily obstetric practice.&#xD;
      In 1993, Handa and Laros defined the arrest of active phase of labor, as failure of labor&#xD;
      progress for 2 hours or more, and in 1994, WHO has proposed labor management partograph in&#xD;
      which protraction is defined as &lt; 1cm/hour cervical dilatation for a minimum of 4 hours.&#xD;
&#xD;
      Prolong labor increase the risks of maternal exhaustion, postpartum hemorrhage, sepsis, fetal&#xD;
      distress and admission to the neonatal intensive care unit. The treatment of prolonged labor&#xD;
      is highly desirable goal of intrapartum care, both from prospective of maternal and fetal&#xD;
      wellbeing and for the provider of the birth services. Management of prolonged labor entails&#xD;
      shorter exposure to pain, anxiety, and stress, and would thus translate into a major&#xD;
      improvement in maternal satisfaction with child birth experience.&#xD;
&#xD;
      Several methods have been used for management of prolonged labor including amniotomy and&#xD;
      oxytocin. Amniotomy can cause infection, and can be combined with oxytocin for better results&#xD;
      while oxytocin can cause uterine hyper stimulation, water intoxication, vomiting, diarrhea,&#xD;
      fetal distress, and neonatal jaundice.&#xD;
&#xD;
      Use of antispasmodics for reducing the duration of labor was first described in 1937 by&#xD;
      Hirsch, who reported a decrease in labor length by two to four hours following intrapartum&#xD;
      administration of an antispasmodic like drug (Syntropan®), mainly among older nulliparous,&#xD;
      this was followed by many studies that investigated the role of antispasmodics in prevention&#xD;
      of prolonged labor, however none of the these studies assessed the value of the antispasmodic&#xD;
      for the treatment of prolonged labor; a recent Cochrane review advised that a rigorously&#xD;
      designed well conducted randomized controlled trial with a large sample size would be&#xD;
      beneficial to answer the question.&#xD;
&#xD;
      Hyoscine butyl bromide is spasmolytic drug that act by competitive antagonism to acetyl&#xD;
      choline at post ganglionic parasympathetic nerve ending. It is claimed to reduce duration of&#xD;
      labor by accelerating cervical dilatation without major side effects. It reduces the spasm of&#xD;
      the smooth muscles. Although the efficacy of Hyoscine has been proven in various studies&#xD;
      there is no clear evidence to recommend their routine use in management of prolonged labor.&#xD;
&#xD;
      The objective of the current study is to determine the use of Hyoscine as an antispasmodic&#xD;
      drug for the management of prolonged labor in nulliparous women at term, managed according to&#xD;
      a standard intrapartum protocol.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Caesarean section rate for failure to progress</measure>
    <time_frame>6 hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Prolonged Labor</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group A, will receive injection Hyoscine butyl bromide 20 mg first dose at the time of amniotomy, and second dose 2 hours after.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group B, will receive normal saline same volume first dose at the time of amniotomy, and second dose 2 hours after.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyoscine butyl bromide</intervention_name>
    <arm_group_label>Group A</arm_group_label>
    <other_name>Buscopan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <arm_group_label>Group B</arm_group_label>
    <other_name>Sodium chloride 0.9%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Nulliparous women.&#xD;
&#xD;
          -  Prolonged labor defined as no progress of labor for 2 hours or more.&#xD;
&#xD;
          -  Gestational age ≥ 37 weeks.&#xD;
&#xD;
          -  Singleton pregnancy.&#xD;
&#xD;
          -  Cephalic presentation.&#xD;
&#xD;
          -  Cervical dilatation ≥ 5 cm.&#xD;
&#xD;
          -  Intact fetal membranes.&#xD;
&#xD;
          -  No evidence of maternal or fetal distress.&#xD;
&#xD;
          -  Average size baby.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Multigravid women.&#xD;
&#xD;
          -  Multifetal pregnancy.&#xD;
&#xD;
          -  History of cervical surgery.&#xD;
&#xD;
          -  Blood pressure &gt; 150/90 mmHg.&#xD;
&#xD;
          -  Mal-presentation and mal-positions.&#xD;
&#xD;
          -  Hypersensitivity to Hyoscine.&#xD;
&#xD;
          -  Contraindication for vaginal delivery.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed Ellaithy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ain Shams University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Labor and delivery ward of Armed Forces Hospital, Southern Region.</name>
      <address>
        <city>Khamis Mushait</city>
        <state>Asir</state>
        <zip>101</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamed Kolkailah, MD</last_name>
      <phone>96672500001</phone>
      <phone_ext>11232</phone_ext>
      <email>prof.mohamed_kolkailah@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Mohamed I Ellaithy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nuzhat Amir</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amel M Ahmed</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Saudi Arabia</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>May 11, 2013</study_first_submitted>
  <study_first_submitted_qc>May 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2013</study_first_posted>
  <last_update_submitted>March 9, 2017</last_update_submitted>
  <last_update_submitted_qc>March 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Mohamed Ellaithy</investigator_full_name>
    <investigator_title>Assistant professor of Obstetrics &amp; Gynecology</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Scopolamine</mesh_term>
    <mesh_term>Bromides</mesh_term>
    <mesh_term>Butylscopolammonium Bromide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

